Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIA-102 in Advanced Gastrointestinal Cancer With Malignant Ascites
NCT05438459Phase 2Recruiting
- Sponsor
- Kyushu University
- Start
- Jun 2022
- Primary completion
- Mar 2032
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GAIA-102 in gastric cancer (GC) and pancreatic cancer (PC) (6 arms), sponsored by Kyushu University. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 2 years and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
GAIA-102
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05438459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438459.